6:01 PM
Mar 30, 2016
 |  BC Extra  |  Clinical News

Renova raising funds for pivotal gene therapy trials

Renova Therapeutics (San Diego, Calif.) plans to begin three pivotal studies by YE16 of gene therapy candidate RT-100 to treat congestive heart failure (CHF), CEO Jack Reich told BioCentury. He said the company also hopes to close a "substantial" series...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >